DOI: 10.1097/mnm.0000000000002225 ISSN: 0143-3636

Association of prostate-specific antigen kinetics with gallium-68 prostate-specific membrane antigen PET/computed tomography positivity in biochemical recurrence after radical prostatectomy

Mounish Nuthalapati, Tanmay Patravale, Nazareth Solomon, Arun Ramdas Menon, Ginil Kumar Pooleri

Introduction

Biochemical recurrence (BCR) after radical prostatectomy occurs in 20–40% of patients. Prostate-specific membrane antigen (PSMA) PET/computed tomography (CT) is the preferred imaging modality for recurrence, but detection rates decline at low prostate-specific antigen (PSA) levels. The role of PSA kinetics in postradical prostatectomy BCR remains unclear. We evaluated the association between PSA kinetics and PSMA PET/CT positivity in postradical prostatectomy BCR.

Materials and methods

We retrospectively analyzed postradical prostatectomy patients (2013–2024) who developed BCR and underwent 68 Ga-PSMA PET/CT. Patients with prior therapy, PSA persistence, inadequate follow-up, or non-PSMA imaging were excluded. Clinicopathological and PSA kinetic variables were compared between groups. Logistic regression assessed associations with PET positivity, and receiver operating characteristic (ROC) analysis identified exploratory cut-offs.

Results

Of 973 men who underwent radical prostatectomy, 64 met the inclusion criteria. Nineteen (29.7%) had positive and 45 (70.3%) had negative scans. Baseline characteristics were comparable. Median PSA at imaging was 0.30 ng/ml. PET-positive patients had higher PSA velocity (PSAV) (0.58 vs. 0.27 ng/ml/year; P = 0.020) and shorter PSA doubling time (PSADT) (3.23 vs. 5.80 months; P = 0.009). On univariable analysis, PSAV [odds ratio (OR): 3.31, P = 0.027), PSADT (OR: 0.86, P = 0.050), and PSA at imaging (OR: 10.68, P = 0.032) were associated with PET positivity. ROC analysis showed moderate discrimination for PSADT (AUC: 0.71) and PSAV (AUC: 0.69).

Conclusion

Shorter PSADT and higher PSAV predicted PSMA PET positivity in men with BCR after radical prostatectomy. Exploratory cut-offs of PSADT less than 3.9 months and PSAV more than 0.54 ng/ml/year were identified but require external validation.

More from our Archive